A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP)
Public ClinicalTrials.gov record NCT06355531. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double-blind, Placebo-controlled, Phase 2 Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 (Oral Formulation) to Slow the Disease Progression of Progressive Supranuclear Palsy (PSP) (PROSPER)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP.
Study identification
- NCT ID
- NCT06355531
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 241 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 50 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 23, 2024 (Actual)
- Primary completion
- Nov 2026 (Estimated)
- Completion
- Nov 2026 (Estimated)
- Last update posted
- Oct 15, 2025
2024 – 2026
United States locations
- U.S. sites
- 12
- U.S. states
- 10
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| The Neurology Center of Southern California - Carlsbad | Carlsbad | California | 92011 | — |
| UCSF Weill Institute for Neurosciences | San Francisco | California | 94158 | — |
| Rocky Mountain Movement Disorders Center | Denver | Colorado | 80113 | — |
| University of Miami Miller School of Medicine | Miami | Florida | 33136 | — |
| Augusta University | Augusta | Georgia | 30912 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Quest Research Institute | Farmington Hills | Michigan | 48334 | — |
| Robert & John M. Bendheim Parkinson and Movement Disorders Center at Mount Sinai | New York | New York | 10029 | — |
| Columbia University Irving Medical Center | New York | New York | 10032 | — |
| Duke Neurology | Durham | North Carolina | 27705 | — |
| Vanderbilt University Medical Center | Nashville | Tennessee | 37212 | — |
| Central Texas Neurology Consultants | Round Rock | Texas | 78681 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 32 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06355531, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 15, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06355531 live on ClinicalTrials.gov.